Investors in RGNX Can Take Lead in REGENXBIO Inc. Securities Fraud Lawsuit

Investors in REGENXBIO Inc. (RGNX) have a chance to take the lead in a securities fraud lawsuit conducted by the Schall Law Firm. The firm is currently investigating claims on behalf of investors who purchased or otherwise acquired REGENXBIO securities between February 26, 2021, and February 28, 2022.

The investigation is focused on whether REGENXBIO and its executives violated federal securities laws by making false and/or misleading statements about the company’s business, operations, and prospects. Specifically, the investigation revolves around allegations that the company misled investors about the efficacy and benefits of its product treatments.

One of the key points of contention is the company’s clinical program for RGX-314, a gene therapy treatment for wet age-related macular degeneration. REGENXBIO claimed positive results from the program, asserting that the treatment had a favorable safety profile and produced notable benefits for patients. However, subsequent developments raised concerns about the accuracy of these claims.

In March 2020, the U.S. Food and Drug Administration (FDA) placed a hold on the company’s Phase II trial of RGX-314, citing concerns about potential adverse events associated with the treatment. This setback led to a significant drop in REGENXBIO’s stock price, causing financial losses for investors who had relied on the company’s previous statements regarding the treatment’s success.

The Schall Law Firm is encouraging investors who suffered losses to participate in the securities fraud lawsuit to seek financial compensation for their damages. By taking part in the legal action, investors have the opportunity to hold REGENXBIO and its executives accountable for any alleged misconduct or misrepresentation that may have led to financial harm.

Investors who purchased REGENXBIO securities during the specified time period and incurred losses as a result of the company’s alleged misrepresentations may be eligible to join the lawsuit. By working with the Schall Law Firm, these investors can actively participate in seeking justice and potentially recovering their financial losses.

The investigation into REGENXBIO’s conduct reflects the firm’s commitment to upholding the rights of investors and holding companies accountable for any deceptive practices that may have harmed shareholders. By pursuing legal action against companies that engage in securities fraud, the Schall Law Firm aims to promote transparency and integrity in the financial markets while advocating for the interests of investors.